Axsome Therapeutics 将来の成長

Future 基準チェック /66

Axsome Therapeutics利益と収益がそれぞれ年間68.9%と38.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に136.5% 68.4%なると予測されています。

主要情報

68.9%

収益成長率

68.4%

EPS成長率

Pharmaceuticals 収益成長	19.6%
収益成長率	38.2%
将来の株主資本利益率	136.5%
アナリストカバレッジ	Good
最終更新日	14 Oct 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BMV:AXSM * - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,062	167	161	219	13
12/31/2025	637	-104	-70	-68	17
12/31/2024	376	-271	-134	-204	17
6/30/2024	291	-309	-168	-167	N/A
3/31/2024	251	-296	-193	-193	N/A
12/31/2023	271	-239	-146	-145	N/A
9/30/2023	223	-202	-143	-142	N/A
6/30/2023	182	-184	-112	-111	N/A
3/31/2023	145	-159	-90	-90	N/A
12/31/2022	50	-187	-117	-117	N/A
9/30/2022	26	-160	-118	-118	N/A
6/30/2022	9	-150	-123	-122	N/A
3/31/2022	N/A	-141	-114	-114	N/A
12/31/2021	N/A	-130	-109	-108	N/A
9/30/2021	N/A	-126	-100	-100	N/A
6/30/2021	N/A	-114	-89	-89	N/A
3/31/2021	N/A	-100	-82	-82	N/A
12/31/2020	N/A	-103	-79	-78	N/A
9/30/2020	N/A	-99	-75	-75	N/A
6/30/2020	N/A	-95	-70	-70	N/A
3/31/2020	N/A	-90	-60	-60	N/A
12/31/2019	N/A	-68	-46	-46	N/A
9/30/2019	N/A	-53	-39	-39	N/A
6/30/2019	N/A	-42	-34	-34	N/A
3/31/2019	N/A	-37	-33	-33	N/A
12/31/2018	N/A	-31	-30	-30	N/A
9/30/2018	N/A	-29	-27	-27	N/A
6/30/2018	N/A	-27	-27	-27	N/A
3/31/2018	N/A	-26	N/A	-27	N/A
12/31/2017	N/A	-29	N/A	-26	N/A
9/30/2017	N/A	-29	N/A	-27	N/A
6/30/2017	N/A	-30	N/A	-26	N/A
3/31/2017	N/A	-29	N/A	-24	N/A
12/31/2016	N/A	-27	N/A	-21	N/A
9/30/2016	N/A	-23	N/A	-16	N/A
6/30/2016	N/A	-21	N/A	-13	N/A
3/31/2016	N/A	-16	N/A	-10	N/A
12/31/2015	N/A	-12	N/A	-7	N/A
9/30/2015	N/A	-10	N/A	-7	N/A
6/30/2015	N/A	-6	N/A	-6	N/A
3/31/2015	N/A	-6	N/A	-5	N/A
12/31/2014	N/A	-6	N/A	-5	N/A

アナリストによる今後の成長予測

収入対貯蓄率: AXSM *は今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 7.9% ) よりも高い成長率であると考えられます。

収益対市場: AXSM *今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: AXSM *今後 3 年以内に収益を上げることが予想されます。

収益対市場: AXSM *の収益 ( 38.2% ) MX市場 ( 7.3% ) よりも速いペースで成長すると予測されています。

高い収益成長: AXSM *の収益 ( 38.2% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AXSM *の自己資本利益率は、3年後には非常に高くなると予測されています ( 136.5 %)。

Axsome Therapeutics 将来の成長

Future 基準チェック /66

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2025

Forecast to breakeven in 2025

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

Axsome Therapeutics, Inc. Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

Axsome Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi (Solriamfetol) Patent Litigation with Sandoz Inc

Second quarter 2024 earnings released: US$1.67 loss per share (vs US$1.54 loss in 2Q 2023)

Axsome Therapeutics, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd

Axsome Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Axsome Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024

Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

Axsome Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers

Axsome Therapeutics, Inc. Presents Results of the Accord Trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease Agitation at its Clinical Trials on Alzheimer's Disease 2023 Conference

Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors

Axsome Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Axsome Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Axsome Therapeutics Initiates Focus Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (Adhd) in Adults

Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Insufficient new directors

Axsome Therapeutics, Inc. to Present New Sunosi Data at Sleep 2023

Axsome Therapeutics, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Forecast to breakeven in 2025

Insufficient new directors

Forecast to breakeven in 2025

Insufficient new directors

Axsome Therapeutics Presents New Data from the Evolve Open-Label Trial Demonstrating Effects of Auvelity® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder At the American College of Neuropsychopharmacology (Acnp) 2022 Annual Meeting

Axsome Therapeutics, Inc. Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

Axsome Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Axsome Therapeutics, Inc. Announces Availability of Auvelity, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

Axsome Therapeutics, Inc. Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the Sharp Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea

Insufficient new directors

Axsome Therapeutics, Inc. Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting

Axsome Therapeutics, Inc. Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research

Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor

Axsome Therapeutics Announces FDA Approval of AUVELITY(TM), the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

No longer forecast to breakeven

Insufficient new directors

Axsome Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Insufficient new directors

Axsome Therapeutics, Inc. Receives from the U.S. Food and Drug Administration

The Gross Law Firm Notifies Shareholders of Axsome Therapeutics, Inc. of A Class Action Lawsuit and A Lead Plaintiff Deadline of July 12, 2022

Axsome Therapeutics Presents New Data from the Gemini Trial Demonstrating Efficacy of Axs-05 on Anhedonia in Patients with Major Depressive Disorder

Axsome Therapeutics, Inc. Presents New Data from the Gemini Trial Demonstrating Efficacy of Axs 05 on Anhedonia in Patients with Major Depressive Disorder

Axsome Therapeutics Announces Positive Results of the Evolve Trial of AXS-05 in Major Depressive Disorder

Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in the Journal of Clinical Psychiatry

Axsome Therapeutics Announces Publication of Pivotal Ascend Phase 2 Trial of AXS-05 in Major Depressive Disorder in the American Journal of Psychiatry

Insufficient new directors

Pomerantz Law Firm Announces the Filing of A Class Action Against Axsome Therapeutics, Inc. and Certain Officers

No longer forecast to breakeven

Insufficient new directors

Axsome Therapeutics, Inc. to Report Q1, 2022 Results on May 02, 2022

Axsome Therapeutics, Inc., Annual General Meeting, Jun 03, 2022

Axsome Therapeutics, Inc. (NasdaqGM:AXSM) agreed to acquire Sunosi® from Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) for $53 million.

Insufficient new directors

Axsome Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Axsome and Baudax Bio, Inc. Enters into Litigation Discontinuance Agreement

Insufficient new directors

Insufficient new directors

Insufficient new directors

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘